Kelly, who has over 25 years of track record in drug discovery and development, will help advance drug development programmes and identification of new drug candidates showing potential to transform the treatment of Duchenne muscular dystrophy.
Additionally, Kelly will be in charge of the organisation's drug discovery and development programme to push research to market for treatment and ultimate cure of this deadly muscle disease in children.
Kelly joins CureDuchenne from Renovis Inc where he served as president and head of US site having previously held senior roles at Amgen (NASDAQ:AMGN), Wyeth (Pfizer) and Wellcome (GlaxoSmithKline).
With the support of CureDuchenne, seven research projects have been advanced into human clinical trials.
Fosun Pharma agrees XH-S004 overseas licensing deal
Itepekimab meets primary endpoint in one of two Phase 3 COPD trials
Inogen secures FDA clearance for SIMEOX 200 Airway Clearance Device
Infex Therapeutics begins Phase IIa trial for RESP-X in NCFB patients
Destiny Pharma launches research on XF-73 for cystic fibrosis MRSA infections
Polarean Imaging enters into trade-in agreement with University of Kansas Medical Center
Sionna Therapeutics doses first healthy subject in SION-109 phase one clinical trial
Arcturus Therapeutics granted FDA Orphan Drug Designation for ARCT-032 to treat cystic fibrosis
SpliSense completes SPL84 first-in-human, Phase one clinical trial for cystic fibrosis treatment
Positive Phase 2, Proof-of-Concept Results for VX-548 Published in New England Journal of Medicine
Inogen acquires Physio-Assist, expanding respiratory product portfolio and global presence